Krsnaa Diagnostics Limited Share Price & Analysis
Price Chart
Fundamentals
Strengths
- Attractively valued vs sector (P/E 16.6x vs industry 50.2x)
- Near 52-week low — potential value zone (₹489)
Concerns
Peer Comparison
| Company | CMP | Mkt Cap | P/E | P/B | ROE % | ROCE % | D/E |
|---|---|---|---|---|---|---|---|
| SUNPHARMA Sun Pharmaceutical Industries Limited | ₹1,758 | ₹4.2L Cr | 33.2 | 5.05 | 16 | 20.5 | 0.07 |
| DIVISLAB Divi's Laboratories Limited | ₹9,559 | ₹2.4L Cr | 79.8 | 15.15 | 16.5 | 22 | 0.01 |
| TORNTPHARM Torrent Pharmaceuticals Limited | ₹4,557 | ₹1.7L Cr | 79.3 | 9.43 | 27.4 | 15.2 | 0.77 |
| ZYDUSLIFE Zydus Lifesciences Limited | ₹1,176 | ₹1.1L Cr | 23.1 | 4.37 | 21.2 | 21.1 | 0.38 |
| APOLLOHOSP Apollo Hospitals Enterprise Limited | ₹8,137 | ₹1.1L Cr | 52.8 | 12.35 | 21.2 | 17.4 | 0.88 |
| CIPLA Cipla Limited | ₹1,366 | ₹1.1L Cr | 30.2 | 3.21 | 11.6 | 15.5 | 0.01 |
| LAURUSLABS Laurus Labs Limited | ₹2,182 | ₹1.1L Cr | 97.4 | 22.22 | 18.3 | 17.8 | 0.46 |
Showing 7 peers in the same sector · Sorted by market cap
Shareholding Pattern
KRSNAA · as of Mar 2026
| Category | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Promoters | 27.03% | 27.03% | 27.17% | 27.17% | 27.24% | 27.24% |
| FII | 3.44% | 3.34% | 3.33% | 3.63% | 4.04% | 3.55% |
| DII | 16.59% | 15.37% | 15.26% | 15.86% | 14.46% | 14.26% |
| Public | 52.94% | 54.27% | 54.23% | 53.34% | 54.27% | 54.94% |
Corporate Events
To consider and approve the financial results for the period ended March 31, 2026 and dividend
Dividend - Rs 2.75 Per Share
Dividend - Rs 2.50 Per Share
Annual General Meeting
Annual General Meeting
Dividend - Rs 2.75 Per Share
Latest News
All newsKrsnaa Diagnostics partners with AZmed for AI radiology platform
*Krsnaa Diagnostics partners with AZmed for AI radiology platform* — Krsnaa Diagnostics has announced a strategic collaboration with global radiology AI firm AZmed to develop an AI-powered platform for enhanced reporting efficiency and scalable growth. The move aims to improve diagnostic accuracy and expand service capacity using advanced AI tools. This partnership could strengthen Krsnaa’s competitive edge in the healthcare diagnostics space. 📊 *STOCKS:* $KRSA | 🏢 *SECTOR:* Healthcare | #MEDIUMIMPACT #AI
Krsnaa Diagnostics announces general updates via NSE filing
*Krsnaa Diagnostics announces general updates via NSE filing.* The company filed routine corporate updates without disclosing specific financials or major developments. Such filings typically include administrative or compliance-related information. Traders should await further details for material impact. 📊 *STOCKS:* $KRISNAA | 🏢 *SECTOR:* Pharma | #LOWIMPACT #CorporateUpdate
Krsnaa Diagnostics issues general corporate updates
*Krsnaa Diagnostics issues general corporate updates.* The filing provides routine disclosures without specific financial or operational details. No **revenue**, **profit**, or **strategic** figures were highlighted. Impact on trading sentiment expected to be minimal. 📊 *STOCKS:* KRISANA | 🏢 *SECTOR:* Pharma | #LOWIMPACT #Corporate
Krsnaa Diagnostics holds annual general meeting
*Krsnaa Diagnostics holds annual general meeting*. Krsnaa Diagnostics Limited conducted its Annual General Meeting on **September 28, 2026**, and submitted the scrutinizers' report to the exchange. Voting results from the meeting were also disclosed. No major announcements or financial updates were reported. 📊 *STOCKS:* $KRISNAA | 🏢 *SECTOR:* Healthcare | #LOWIMPACT #AGM
Krsnaa Diagnostics issues general updates via NSE filing
*Krsnaa Diagnostics issues general updates via NSE filing.* No specific financial or operational details were disclosed. The nature of the update remains unspecified in the regulatory filing. Traders should await further clarity from the company. 📊 *STOCKS:* KRISANA | 🏢 *SECTOR:* Pharma | #LOWIMPACT #CorporateUpdate
Krsnaa Diagnostics publishes mandatory newspaper notice
*Krsnaa Diagnostics publishes mandatory newspaper notice.* This is a routine regulatory requirement under corporate norms. No financial or operational details were disclosed. Such filings are standard for public disclosures. 📊 *STOCKS:* KRISANA | 🏢 *SECTOR:* Healthcare | #LOWIMPACT #CorporateFiling
Krsnaa Diagnostics issues general corporate updates
*Krsnaa Diagnostics issues general corporate updates.* The filing provides routine information without disclosing specific financials or strategic moves. Such updates typically do not alter business fundamentals. Investors await further clarity on operations or governance. 📊 *STOCKS:* KRISANA | 🏢 *SECTOR:* Pharma | #LOWIMPACT #Corporate
Krsnaa Diagnostics shares up on investor presentation
*Krsnaa Diagnostics shares rose after an investor presentation.* The update highlighted **₹1,100 crore** revenue run rate and expansion plans. No major financial surprises or guidance changes were announced. The stock reacted positively despite no immediate triggers. 📊 *STOCKS:* KRISANA | 🏢 *SECTOR:* Healthcare | #LOWIMPACT #InvestorPresentation
Financials
Quarterly Results
| Metric | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹181 Cr 12.1% | ₹206 Cr 6.7% | ₹193 Cr 3.8% | ₹186 Cr 6.3% | ₹175 Cr 5.9% | ₹186 Cr 9.4% | ₹170 Cr 2.4% | ₹166 Cr |
| Op. Profit | ₹46 Cr 22.0% | ₹59 Cr 15.7% | ₹51 Cr 3.8% | ₹53 Cr 17.8% | ₹45 Cr 8.2% | ₹49 Cr 14.0% | ₹43 Cr 2.3% | ₹44 Cr |
| OPM | 26.0% 10.3% | 29.0% 7.4% | 27.0% 3.6% | 28.0% 7.7% | 26.0% 3.7% | 27.0% 8.0% | 25.0% 3.8% | 26.0% |
| Net Profit | ₹15 Cr 37.5% | ₹24 Cr 14.3% | ₹21 Cr 0.0% | ₹21 Cr 10.5% | ₹19 Cr 5.0% | ₹20 Cr 11.1% | ₹18 Cr 5.3% | ₹19 Cr |
| EPS (₹) | 4.7 36.3% | 7.38 16.6% | 6.33 1.1% | 6.4 6.5% | 6.01 1.0% | 6.07 9.4% | 5.55 4.3% | 5.8 |
Values in ₹ Cr · Source: Screener.in
Annual Profit & Loss
| Metric | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2017 | Mar 2016 |
|---|---|---|---|---|---|---|---|
| Revenue | ₹773 Cr 7.8% | ₹717 Cr 15.6% | ₹620 Cr 27.3% | ₹487 Cr 7.0% | ₹455 Cr 645.9% | ₹61 Cr 56.4% | ₹39 Cr |
| Expenses | ₹561 Cr 6.5% | ₹527 Cr 10.9% | ₹475 Cr 30.1% | ₹365 Cr 12.7% | ₹324 Cr 671.4% | ₹42 Cr 40.0% | ₹30 Cr |
| Op. Profit | ₹212 Cr 11.6% | ₹190 Cr 31.9% | ₹144 Cr 18.0% | ₹122 Cr 7.6% | ₹132 Cr 594.7% | ₹19 Cr 111.1% | ₹9 Cr |
| OPM | 27.0% 0.0% | 27.0% 17.4% | 23.0% 8.0% | 25.0% 13.8% | 29.0% 6.5% | 31.0% 34.8% | 23.0% |
| Other Income | ₹43 Cr 65.4% | ₹26 Cr 52.9% | ₹17 Cr 10.5% | ₹19 Cr 26.7% | ₹15 Cr 650.0% | ₹2 Cr 33.3% | ₹3 Cr |
| Interest | ₹34 Cr 36.0% | ₹25 Cr 56.3% | ₹16 Cr 100.0% | ₹8 Cr 55.6% | ₹18 Cr 100.0% | ₹9 Cr 0.0% | ₹9 Cr |
| Depreciation | ₹90 Cr 2.3% | ₹88 Cr 17.3% | ₹75 Cr 38.9% | ₹54 Cr 31.7% | ₹41 Cr 241.7% | ₹12 Cr 100.0% | ₹6 Cr |
| PBT | ₹130 Cr 26.2% | ₹103 Cr 47.1% | ₹70 Cr 12.5% | ₹80 Cr 8.0% | ₹87 Cr | ₹0 Cr 100.0% | ₹-3 Cr |
| Tax % | 22.0% 8.3% | 24.0% 26.3% | 19.0% 17.4% | 23.0% 9.5% | 21.0% 88.3% | 180.0% 267.3% | 49.0% |
| Net Profit | ₹101 Cr 29.5% | ₹78 Cr 36.8% | ₹57 Cr 8.1% | ₹62 Cr 8.8% | ₹68 Cr | ₹0 Cr 100.0% | ₹-5 Cr |
| EPS (₹) | 31.27 30.1% | 24.04 36.6% | 17.6 11.0% | 19.78 9.2% | 21.78 15657.1% | -0.14 98.5% | -9.53 |
| Div Payout | 0.0% 100.0% | 11.0% 21.4% | 14.0% 0.0% | 14.0% 27.3% | 11.0% | 0.0% | 0.0% |
Values in ₹ Cr · Source: Screener.in
Balance Sheet
| Item | Mar 2026 | Sep 2025 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2017 | Mar 2016 |
|---|---|---|---|---|---|---|---|---|
Liabilities | ||||||||
| Equity Capital | ₹16 Cr 0.0% | ₹16 Cr 0.0% | ₹16 Cr 0.0% | ₹16 Cr 0.0% | ₹16 Cr 0.0% | ₹16 Cr 220.0% | ₹5 Cr 0.0% | ₹5 Cr |
| Reserves | ₹964 Cr 6.3% | ₹907 Cr 4.6% | ₹867 Cr 9.2% | ₹794 Cr 9.8% | ₹723 Cr 8.1% | ₹669 Cr 11050.0% | ₹6 Cr 0.0% | ₹6 Cr |
| Borrowings | ₹534 Cr 86.7% | ₹286 Cr 40.2% | ₹204 Cr 27.5% | ₹160 Cr 400.0% | ₹32 Cr 22.0% | ₹41 Cr 59.8% | ₹102 Cr 22.1% | ₹131 Cr |
| Other Liabilities | ₹309 Cr 3.7% | ₹298 Cr 55.2% | ₹192 Cr 4.5% | ₹201 Cr 46.7% | ₹137 Cr 8.7% | ₹150 Cr 87.5% | ₹80 Cr 81.8% | ₹44 Cr |
| Total Liabilities | ₹1.8K Cr 21.0% | ₹1.5K Cr 17.9% | ₹1.3K Cr 9.2% | ₹1.2K Cr 28.9% | ₹908 Cr 3.8% | ₹875 Cr 355.7% | ₹192 Cr 3.2% | ₹186 Cr |
Assets | ||||||||
| Fixed Assets | ₹656 Cr 4.0% | ₹683 Cr 1.9% | ₹670 Cr 3.6% | ₹647 Cr 37.4% | ₹471 Cr 22.0% | ₹386 Cr 194.7% | ₹131 Cr 77.0% | ₹74 Cr |
| CWIP | ₹208 Cr 593.3% | ₹30 Cr 900.0% | ₹3 Cr 70.0% | ₹10 Cr 60.0% | ₹25 Cr 10.7% | ₹28 Cr 366.7% | ₹6 Cr 70.0% | ₹20 Cr |
| Investments | ₹57 Cr 78.1% | ₹32 Cr 0.0% | ₹32 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr 100.0% | ₹1 Cr 0.0% | ₹1 Cr |
| Other Assets | ₹902 Cr 18.4% | ₹762 Cr 33.0% | ₹573 Cr 11.7% | ₹513 Cr 24.5% | ₹412 Cr 10.6% | ₹461 Cr 738.2% | ₹55 Cr 39.6% | ₹91 Cr |
| Total Assets | ₹1.8K Cr 21.0% | ₹1.5K Cr 17.9% | ₹1.3K Cr 9.2% | ₹1.2K Cr 28.9% | ₹908 Cr 3.8% | ₹875 Cr 355.7% | ₹192 Cr 3.2% | ₹186 Cr |
Values in ₹ Cr · Source: Screener.in
Cash Flow Statement
| Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2017 | Mar 2016 |
|---|---|---|---|---|---|---|---|
| Operating CF | ₹143 Cr 64.4% | ₹87 Cr 262.5% | ₹24 Cr 68.4% | ₹76 Cr 40.6% | ₹128 Cr 100.0% | ₹64 Cr 378.3% | ₹-23 Cr |
| Investing CF | ₹-396 Cr 296.0% | ₹-100 Cr 22.5% | ₹-129 Cr 18.3% | ₹-109 Cr 54.8% | ₹-241 Cr 346.3% | ₹-54 Cr 14.9% | ₹-47 Cr |
| Financing CF | ₹279 Cr 1892.9% | ₹14 Cr 83.3% | ₹84 Cr 354.5% | ₹-33 Cr 118.8% | ₹176 Cr 529.3% | ₹-41 Cr 139.0% | ₹105 Cr |
| Net Cash Flow | ₹26 Cr 2500.0% | ₹1 Cr 105.0% | ₹-20 Cr 69.7% | ₹-66 Cr 203.1% | ₹64 Cr 306.5% | ₹-31 Cr 186.1% | ₹36 Cr |
| Free Cash Flow | ₹-72 Cr 200.0% | ₹-24 Cr 85.8% | ₹-169 Cr 191.4% | ₹-58 Cr 1833.3% | ₹-3 Cr 130.0% | ₹10 Cr 114.5% | ₹-69 Cr |
Values in ₹ Cr · Source: Screener.in
Key Ratios History
| Metric | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2017 | Mar 2016 |
|---|---|---|---|---|---|---|---|
| Debtor Days | 140d 0.7% | 141d 35.6% | 104d 89.1% | 55d 19.6% | 46d 45.2% | 84d 6.3% | 79d |
| Inventory Days | 54d | — | — | — | — | 24d 14.3% | 21d |
| Days Payable | 129d | — | — | — | — | 100d 31.6% | 76d |
| Cash Conv. Cycle | 65d 53.9% | 141d 35.6% | 104d 89.1% | 55d 19.6% | 46d 475.0% | 8d 66.7% | 24d |
| Working Capital Days | 48d 128.6% | 21d 200.0% | -21d 290.9% | 11d 147.8% | -23d 79.6% | -113d 63.8% | -69d |
| ROCE | 13.0% 8.3% | 12.0% 20.0% | 10.0% 16.7% | 12.0% | — | 7.0% | — |
Source: Screener.in · Lower days = better efficiency